Cargando…

Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival

Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 3...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisk, Gabriella, Helde Frankling, Maria, Warnqvist, Anna, Björkhem-Bergman, Linda, Hedman, Mattias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031780/
https://www.ncbi.nlm.nih.gov/pubmed/35455016
http://dx.doi.org/10.3390/life12040525
_version_ 1784692476440739840
author Frisk, Gabriella
Helde Frankling, Maria
Warnqvist, Anna
Björkhem-Bergman, Linda
Hedman, Mattias
author_facet Frisk, Gabriella
Helde Frankling, Maria
Warnqvist, Anna
Björkhem-Bergman, Linda
Hedman, Mattias
author_sort Frisk, Gabriella
collection PubMed
description Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 384). If the patients were able to come home again was estimated using logistic regression and odds ratios (OR) and survival by using Cox regression. The median age in the cohort was 65.6 years, the median survival following WBRT was 2.4 months (interquartile range (IQR) 1.2–6.2 months), and 84 (22%) patients were not able to come home after treatment. Significantly more males could come home again after WBRT compared to women (OR = 0.37, 95%CI 0.20–0.68). Patients with performance status scores WHO 3–4 had a median survival of 1.0 months, hazard ratio (HR) = 4.69 (95%CI 3.31–6.64) versus WHO score 0–1. Patients admitted to a palliative ward before WBRT had a median survival of 0.85 months, HR = 2.26 (95%CI 1.53–3.34) versus being at home. In conclusion, patients treated with WBRT had a short median survival and 20% could not be discharged from the hospital following treatment. Significantly more women did not come home again.
format Online
Article
Text
id pubmed-9031780
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90317802022-04-23 Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival Frisk, Gabriella Helde Frankling, Maria Warnqvist, Anna Björkhem-Bergman, Linda Hedman, Mattias Life (Basel) Article Whole-brain radiotherapy (WBRT) as a treatment for brain metastases has been questioned over the last years. This study aimed to evaluate health care levels and survival after WBRT in a cohort of lung cancer patients with brain metastases receiving WBRT in Stockholm, Sweden, from 2008 to 2019 (n = 384). If the patients were able to come home again was estimated using logistic regression and odds ratios (OR) and survival by using Cox regression. The median age in the cohort was 65.6 years, the median survival following WBRT was 2.4 months (interquartile range (IQR) 1.2–6.2 months), and 84 (22%) patients were not able to come home after treatment. Significantly more males could come home again after WBRT compared to women (OR = 0.37, 95%CI 0.20–0.68). Patients with performance status scores WHO 3–4 had a median survival of 1.0 months, hazard ratio (HR) = 4.69 (95%CI 3.31–6.64) versus WHO score 0–1. Patients admitted to a palliative ward before WBRT had a median survival of 0.85 months, HR = 2.26 (95%CI 1.53–3.34) versus being at home. In conclusion, patients treated with WBRT had a short median survival and 20% could not be discharged from the hospital following treatment. Significantly more women did not come home again. MDPI 2022-04-01 /pmc/articles/PMC9031780/ /pubmed/35455016 http://dx.doi.org/10.3390/life12040525 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Frisk, Gabriella
Helde Frankling, Maria
Warnqvist, Anna
Björkhem-Bergman, Linda
Hedman, Mattias
Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title_full Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title_fullStr Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title_full_unstemmed Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title_short Evaluation of Whole Brain Radiotherapy among Lung Cancer Patients with Brain Metastases in Relation to Health Care Level and Survival
title_sort evaluation of whole brain radiotherapy among lung cancer patients with brain metastases in relation to health care level and survival
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9031780/
https://www.ncbi.nlm.nih.gov/pubmed/35455016
http://dx.doi.org/10.3390/life12040525
work_keys_str_mv AT friskgabriella evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival
AT heldefranklingmaria evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival
AT warnqvistanna evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival
AT bjorkhembergmanlinda evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival
AT hedmanmattias evaluationofwholebrainradiotherapyamonglungcancerpatientswithbrainmetastasesinrelationtohealthcarelevelandsurvival